Novartis AG - ADR
NVS
Market Cap$214.86B
Close$
Earnings Call Q4 2023
January 31, 2024 - AI Summary
Novartis reported strong full-year results for 2023, with sales up 10% and core operating income up 18% in constant currencies.
The company provided updated guidance for 2024, expecting mid-single digit sales growth and high single-digit core operating income growth. This guidance is considered prudent due to the potential impact of generics and assumes no US generic entry for Entresto in 2024.
Novartis extended its midterm guidance, projecting a 5% constant currency sales growth from 2023 to 2028 and aiming for a core operating income margin of 40% or higher by 2027.
Exclusive for Stockcircle Pro members
Sign up
$97.76
5.6% upside
Current Fair Value
5.6% upsideUndervalued by 5.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $214.86 Billion |
|---|---|
| Enterprise Value | $226.78 Billion |
| Dividend Yield | $3.7772 (4.0%) |
| Earnings per Share | $7.1 |
| Beta | 0.31 |
| Outstanding Shares | 2,277,477,752 |
| Avg 30 Day Volume | 1,449,988 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 14.47 |
|---|---|
| PEG | 3.02 |
| Price to Sales | 4.63 |
| Price to Book Ratio | 4.63 |
| Enterprise Value to Revenue | 4.86 |
| Enterprise Value to EBIT | 22.05 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.56 |
Revenue Sources
No data
ESG Score
No data
About Novartis AG
CEO: Vasant Narasimhan Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segm...